<p>在今天发布的一份报告中，H.C. Wainwright 的 Patrick Trucchio 重申了对 Pharvaris 的买入评级，目标价为 60.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Trucchio 关注医疗保健行业，重点关注 Atai Beckley N.V.、Definium Therapeutics 和 Alnylam Pharma 等股票。根据 TipRanks，Trucchio 推荐股票的平均回报率为 27.8%，成功率为 52.26%。</p>
<p>除了 H.C. Wainwright，Pharvaris 还在昨天的报告中获得了 Citizens JMP 的 Jonathan Wolleben 的买入评级。然而，今天，美国银行证券对 Pharvaris（NASDAQ: PHVS）维持了持有评级。</p>

PHVS

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

<p>H.C. Wainwright 的 Patrick Trucchio 重申了对 Pharvaris (PHVS) 的买入评级，目标价为 60.00 美元。Trucchio 负责医疗保健行业，平均回报率为 27.8%，股票推荐的成功率为 52.26%。此外，Citizens JMP 的 Jonathan Wolleben 最近也对 Pharvaris 发布了买入评级，而美国银行证券则维持了该股票的持有评级</p>

<p>In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Pharvaris, with a price target of $60.00.</p>
<div class="lb-trans"><p>在今天发布的一份报告中，H.C. Wainwright 的 Patrick Trucchio 重申了对 Pharvaris 的买入评级，目标价为 60.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Trucchio covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Definium Therapeutics, and Alnylam Pharma. According to TipRanks, Trucchio has an average return of 27.8% and a 52.26% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Trucchio 关注医疗保健行业，重点关注 Atai Beckley N.V.、Definium Therapeutics 和 Alnylam Pharma 等股票。根据 TipRanks，Trucchio 推荐股票的平均回报率为 27.8%，成功率为 52.26%。</p>
</div><p>In addition to H.C. Wainwright, Pharvaris also received a Buy from Citizens JMP’s Jonathan Wolleben in a report issued yesterday. However, today, Bank of America Securities maintained a Hold rating on Pharvaris (NASDAQ: PHVS).</p>
<div class="lb-trans"><p>除了 H.C. Wainwright，Pharvaris 还在昨天的报告中获得了 Citizens JMP 的 Jonathan Wolleben 的买入评级。然而，今天，美国银行证券对 Pharvaris（NASDAQ: PHVS）维持了持有评级。</p>
</div>

Pharvaris (PHVS) Receives a Buy from H.C. Wainwright

Tip Ranks

Pharvaris BV

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

标普全球医疗股指数 ETF - iShares

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - SPDR

AtaiBeckley

Definium Therapeutics

阿里拉姆制药

Citizens Financial

美国银行

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Pharvaris (PHVS) 获得了 H.C. Wainwright 的买入评级